STA-5326 in Crohn's Disease Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

November 30, 2004

Conditions
Crohn's Disease
Interventions
DRUG

STA-5326

Trial Locations (18)

10021

Long Island Clinical Research, Great Neck

14607

Rochester Institute for Digestive Diseases and Sciences, Inc, Rochester

16602

Blair Gastroenterology Associates, Altoona

27612

Wake Research Associates, Raleigh

28262

Carolina Research Associates, Charlotte

32789

Shafran Gastoenterology Center, Winter Park

33162

Venture Research Institute, LLC, North Miami Beach

37205

Nashville Medical Research Institute, Nashville

38120

Memphis Gastroenterology Group, Memphis

60611

Northwestern University, Chicago

60637

University of Chicago, Chicago

66614

Heart of America Research Institute, Topeka

85712

Advanced Clinical Therapeutics, Tucson

92801

Advanced Clinical Research Institute, Anaheim

02114

Massachusetts General Hospital, Boston

02118

Boston Medical Center, Boston

02215

Brigham and Women's Hospital, Boston

Unknown

West Hills GI, Portland

All Listed Sponsors
lead

Synta Pharmaceuticals Corp.

INDUSTRY

NCT00088062 - STA-5326 in Crohn's Disease Patients | Biotech Hunter | Biotech Hunter